I posted elswhere that I have confidence in this Bioeffective product commercialisation track for BPO/SLA. If folk care to explore the background Dr Sally Colgan [SCEC Pty Ltd], who is the BioProspect EGUS BioA trial consultant, they could expect that APVMA work has Is & Ts all done to spec. In addition, as BioA already has TGA approval in Australia the approval road may not be as long as some are thinking.
BPO Price at posting:
2.3¢ Sentiment: Hold Disclosure: Held